2025年开年以来,港交所18A上市的Biotech公司市值重塑。在纳斯达克、A股以及港交所三地上市的百济神州以接近2000亿港元市值依旧遥遥领先;信达生物和康方生物则在探花和榜眼位置轮番交替;科伦博泰生物坐拥第四宝座;再鼎医药凭借非凡的市值管理能力位居第五。相比一年前的港股18A市值排名,比较让医药财经小编意外的是,荣昌生物的港股市值已经跌落到十名开外,港股市值不足80亿港元,甚至低于2024年...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.